Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine
European Pharmaceutical Journal · 2016
DOI: 10.1515/afpuc-2016-0008 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Pharmaceutical Journal, 2016. Verfasst von M. Oppa und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Depression
Abstract (Originalsprache)
In the previous research at Jessenius Faculty of Medicine in Martin has been studied depression and its treatment from the aspects of the quality of life and functioning of the patients, as well as comparing the efficacy and safety of venlafaxine versus venlafaxine and olanzapine treatment. Last years have been studied the parameters of the autonomic nervous system in the context of depression. Our new work will build on these findings, during the exploration of efficacy and safety of a novel antidepressant vortioxetine in monotherapy and in combination with olanzapine. Since combination of vortixetine and olanzapine is not yet understood, it is unknown whether the effect of the treatment of depressive symptoms and associated problems will be stronger and faster compared to vortioxetine monotherapy.
Zitieren
APA
Oppa, M., Kulhan, T., Nosáľová, G., & Ondrejka, I. (2016). Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine. European Pharmaceutical Journal. https://doi.org/10.1515/afpuc-2016-0008
Vancouver
Oppa M, Kulhan T, Nosáľová G, Ondrejka I. Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine. European Pharmaceutical Journal. 2016. doi:10.1515/afpuc-2016-0008
BibTeX
@article{Oppa2016,
author = {Oppa, M. and Kulhan, T. and Nosáľová, G. and Ondrejka, I.},
title = {Acute phase of depression treatment - current research and its perspectives on Jessenius Faculty of Medicine},
journal = {European Pharmaceutical Journal},
year = {2016},
doi = {10.1515/afpuc-2016-0008}
}
EUVIMED